ArticleThe Journal of biological chemistry2018
Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.
Article in The Journal of biological chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Elucidating the Mechanisms of SA-4-1BBL-Mediated Cancer Immunoprevention Through Advanced Informatics Approaches.Biomolecules · 2026Article
- Multifaceted roles of Galectins: from carbohydrate binding to targeted cancer therapy.Biomarker research · 2025Review
- 4-1BB immunotherapy: advances and hurdles.Experimental & molecular medicine · 2024Review
- Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists.Frontiers in immunology · 2023Review
- Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor.Cancer immunology, immunotherapy : CII · 2022Article
- Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia.Nature communications · 2022Article
- Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?Cancers · 2021Review
- TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.Communications biology · 2021Article
- 4-1BBL as a Mediator of Cross-Talk between Innate, Adaptive, and Regulatory Immunity against Cancer.International journal of molecular sciences · 2021Review
- Glycosylation of Immune Receptors in Cancer.Cells · 2021Review
- Structures of mouse and human GITR-GITRL complexes reveal unique TNF superfamily interactions.Nature communications · 2021Article
- Optimization of T Cell Redirecting Strategies: Obtaining Inspirations From Natural Process of T Cell Activation.Frontiers in immunology · 2021Review
- Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.Journal for immunotherapy of cancer · 2021Article
- Early loss of T lymphocyte 4-1BB receptor expression is associated with higher short-term mortality in alcoholic hepatitis.PloS one · 2021Article
- Novel Discoveries in Immune Dysregulation in Inborn Errors of Immunity.Frontiers in immunology · 2021Review
- An engineered 4-1BBL fusion protein with "activity on demand".Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation.Oncogenesis · 2020Article
- A universal reporter cell line for bioactivity evaluation of engineered cytokine products.Scientific reports · 2020Article
- The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity.Frontiers in immunology · 2020Review
- Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding.The Journal of biological chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
4-1BB (CD137) is a TNF receptor superfamily (TNFRSF) member that is thought to undergo receptor trimerization upon binding to its trimeric TNF superfamily ligand (4-1BBL) to stimulate immune responses. 4-1BB also can bind to the tandem repeat-type lectin galectin-9 (Gal-9), and signaling through mouse (m)4-1BB is reduced in galectin-9 (Gal-9)-deficient mice, suggesting a pivotal role of Gal-9 in m4-1BB activation. Here, using sulfur-SAD phasing, we determined the crystal structure of m4-1BB to 2.2-Å resolution. We found that similar to other TNFRSFs, m4-1BB has four cysteine-rich domains (CRDs). However, the organization of CRD1 and the orientation of CRD3 and CRD4 with respect to CRD2 in the m4-1BB structure distinctly differed from those of other TNFRSFs. Moreover, we mapped two Asn residues within CRD4 that are
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.